
Notice of rescheduled AGM

of the meeting date, by choosing one of the following options:



| 1. Shareholders can download a copy of the Proxy voting form from www.novacyt.com/investors for completion and return to investor.relations@novacyt.com until 10.59pm BST/11.59pm CEST on Sunday 17 July 2022. All submissions must include an electronic signature and be accompanied by evidence of shareholding, for example a share certificate or statement of holding. |
|--|
| 2. Shareholders can vote on-line until 2pm BST/3pm CEST on Tuesday 19 July 2022 using the Votaccess portal http://www.actionnaire.cic-marketsolutions.eu if securities held on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank or JP Morgan. |
| The Second Convening Notice of AGM will be published in the Bulletin des Annonces Légales Obligatoires (BALO) and posted to nominative shareholders on Friday 24 June 2022. |
| - End - |
| Contacts |
| Novacyt SA |
| David Allmond, Chief Executive Officer |
| James McCarthy, Chief Financial Officer |
| +44 (0)1276 600081 |
| SP Angel Corporate Finance LLP (Nominated Adviser and Broker) |
| Matthew Johnson / Charlie Bouverat (Corporate Finance) |
| Vadim Alexandre / Rob Rees (Corporate Broking) |
| +44 (0)20 3470 0470 |
| Numis Securities Limited (Joint Broker) |
| Freddie Barnfield / James Black / Duncan Monteith |
| +44 (0)20 7260 1000 |
| Allegra Finance (French Listing Sponsor) |
| Rémi Durgetto / Yannick Petit |

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAZZGZVZMLGZZM